The Kitasato Institute

Mitsui Sugar Co., Ltd.

Carna Biosciences, Inc.

Masato Iwatsuki

Satoshi Omura

Kazuhiko Otoguro

Yoko Takahashi

Aki Ishiyama

Hiroshi Tomoda

Masaaki Sawa

Haruki Yamada

Kazuro Shiomi

Jun Kashimura

Toshikazu Kawai

Masami Mizu

Kenji Koge

Yuko Uno

Takuji Nakashima

Hiroaki Kiyohara

Yuko Asamitsu

Atsuko Matsumoto

Rei Hokari

The present invention provides a novel 2,4,6-substituted pyrimidine derivative, which is a compound represented by formula (I) (in the formula, ring A is a 6-membered heteroaryl group having at least one N atom optionally substituted with R1, R2, and R3; Z is an optionally substituted alkoxy group, an optionally substituted amino group, an optionally substituted heterocycloalkyl group, or an optionally substituted heteroaryl group; and R1, R2, and R3 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted alkoxy group, an optionally substituted cycloalkyloxy group, an optionally substituted heterocycloalkyloxy group, an optionally substituted phenoxy group, an optionally substituted amino group, a nitro group, and a hydroxy group) or a pharmaceutically acceptable salt thereof.

Pyrimidine derivative having antimalarial activity

The present invention provides a Peyer's patch activator containing a polysaccharide obtained from sugar cane as an active ingredient, wherein the polysaccharide contains &#x3b1;-glucan as a main component and has a peak molecular weight within a range of 720,000 to 1,080,000, with a proportion of glucose in all component sugars being 80% or more, and proportions of nonreducing terminal glucose and &#x3b1;-1,6-linked glucose being 20 to 30% and 15 to 25%, respectively.

Peyer's patch activator

The present invention addresses the problem of providing an anti-trypanosomal drug having a novel skeleton, in order to solve issues that occur with conventional technologies. The present invention is based on the discovery of a microbe that produces an anti-trypanosomal drug having a novel skeleton. Specifically, this invention provides: a compound indicated by formula (I) having a trypanosomal inhibitory activity; an analog thereof; a production method therefor; and asp. K10-0216 strain that produces said compound.

Mangromicin compound and production method therefor

The present invention is comprised of culturing a microorganism having ability to produce K01-B0171-B substance and/or K01-B0171-C substance in a medium, accumulating K01-B0171-B substance and/or K01-B0171-C substance in a culture fluid and isolating K01-B0171-B substance and/or, K01-B0171-C substance from the culture fluid. The obtained K01-B0171-B substance, K01-B0171-C substance or a composition of these substances is expected to be useful as a medicament of antituberculous agent.

Substances K01-B0171 and process for producing the same

Growing community of inventors

Tokyo, Japan

Masato Iwatsuki